{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:47:06Z","timestamp":1782107226632,"version":"3.54.5"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Expedited pathways in the United States (U.S.), European Union (EU), and Japan (JP) enable earlier access to innovative therapies for rare and serious diseases. In 2025, Japan explicitly introduced revocation provisions to its Conditional Early Approval (CEA). Considering the challenges in a related prior scheme\u2014conditional and time\u2010limited approval for regenerative medical products\u2014particularly withdrawals prior to full approval, this study examined oncology cases under the U.S. Accelerated Approval (AA) and EU Conditional Marketing Authorization (CMA) pathways to identify operational challenges for revocation under Japan's CEA. We conducted a descriptive comparative analysis of oncology drugs granted AA or CMA between January 2015 and December 2024 using publicly available data. Post\u2010authorization outcomes and JP approval\/development status were summarized. AA encompassed 97 products (138 indications), CMA included 27 products (30 indications), and CEA covered 4 products (4 indications). Approximately half of AA\/CMA indications were approved in Japan, while some remained undeveloped. The mean time from AA to full approval was 2.7\u2009years and to withdrawal was 3.6\u2009years. Overall, about 15% of AA indications were withdrawn, primarily due to failed confirmatory trials; 8 products\/10 indications underwent Oncologic Drugs Advisory Committee deliberations prior to withdrawal or continuation. With recent policy changes aligning CEA eligibility with AA\/CMA, broader implementation of CEA is anticipated. For revocation operations, three priorities emerge: (1) timely confirmatory trials and alternative approaches to reduce uncertainty; (2) transparent public evaluation and decision\u2010making; and (3) flexible patient\u2010access systems following withdrawal. Continued discussion is required to support effective use of CEA.<\/jats:p>","DOI":"10.1111\/cts.70642","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:35:43Z","timestamp":1781850943000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With\n                    <scp>FDA<\/scp>\n                    \/\n                    <scp>EMA<\/scp>"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5253-4535","authenticated-orcid":false,"given":"Takahiro","family":"Handa","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences Tokyo University of Science  Tokyo Japan"},{"name":"Late Development Oncology TA Division AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9819-749X","authenticated-orcid":false,"given":"Arata","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences Tokyo University of Science  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9199-540X","authenticated-orcid":false,"given":"Mayumi","family":"Shikano","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences Tokyo University of Science  Tokyo Japan"},{"name":"Faculty of Pharmaceutical Sciences Tokyo University of Science  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-381X","authenticated-orcid":false,"given":"Rika","family":"Wakao","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences Tokyo University of Science  Tokyo Japan"},{"name":"Faculty of Pharmaceutical Sciences Tokyo University of Science  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway Guidance for Industry","author":"US Food and Drug Administration","year":"2019"},{"key":"e_1_2_9_3_1","volume-title":"COMMISSION REGULATION (EC) No 507\/2006 of 29 March 2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No 726\/2004 of the European Parliament and of the Council","author":"European Medicines Agency","year":"2006"},{"key":"e_1_2_9_4_1","volume-title":"Implementation of a Conditional Early Approval System for Pharmaceutical Products","author":"Ministry of Health, Labour and Welfare","year":"2017"},{"key":"e_1_2_9_5_1","unstructured":"US Food and Drug Administration \u201cCancer Accelerated Approvals \u201dhttps:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/ongoing\u2010cancer\u2010accelerated\u2010approvals."},{"key":"e_1_2_9_6_1","unstructured":"European Medicines Agency \u201cConditional Marketing Authorisation \u201dhttps:\/\/www.ema.europa.eu\/en\/human\u2010regulatory\u2010overview\/marketing\u2010authorisation\/conditional\u2010marketing\u2010authorisation."},{"key":"e_1_2_9_7_1","volume-title":"Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics Guidance for Industry","author":"US Food and Drug Administration","year":"2023"},{"key":"e_1_2_9_8_1","volume-title":"Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway Guidance for Industry","author":"US Food and Drug Administration","year":"2025"},{"key":"e_1_2_9_9_1","volume-title":"European Medicines Agency Post\u2010Authorisation Procedural Advice for Users of the Centralised Procedure","author":"European Medicines Agency","year":"2009"},{"key":"e_1_2_9_10_1","volume-title":"Partial Revision of \u201cHandling of Conditional Approval of Drugs\u201d PMSB\/ELD Notification No. 1023\u20132 October 23","author":"Ministry of Health, Labour and Welfare","year":"2024"},{"key":"e_1_2_9_11_1","volume-title":"Act to Partially Amend the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc. (Act No. 37 of 2025)","author":"Ministry of Health, Labour and Welfare","year":"2025"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13536"},{"key":"e_1_2_9_13_1","first-page":"225","article-title":"Regulatory Aspects of Regenerative Medical Products in Japan: The PMDA Perspective","volume":"15","author":"Maruyama Y.","year":"2025","journal-title":"Regulatory Science of Medical Products"},{"key":"e_1_2_9_14_1","unstructured":"TERUMO Japan \u201cDeliberation Results on \u2018HeartSheet\u2019 by the Pharmaceutical Affairs and Food Sanitation Council Ministry of Health Labour and Welfare \u201dhttps:\/\/www.terumo.co.jp\/newsrelease\/detail\/20240720\/10371."},{"key":"e_1_2_9_15_1","unstructured":"AnGes INC \u201cStrategic Change in Product Development\u2010Collategene (HGF Gene Therapy Product) \u201dhttps:\/\/www.anges.co.jp\/pdf_news\/public\/21yjDiabXEhaOPF7rDYVZa9gpRkiQNKY.pdf."},{"key":"e_1_2_9_16_1","unstructured":"US Food and Drug Administration \u201cDrugs@FDA: FDA\u2010Approved Drugs \u201dhttps:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"e_1_2_9_17_1","unstructured":"US Food and Drug Administration \u201cOncologic Drugs Advisory Committee \u201dhttps:\/\/www.fda.gov\/advisory\u2010committees\/human\u2010drug\u2010advisory\u2010committees\/oncologic\u2010drugs\u2010advisory\u2010committee."},{"key":"e_1_2_9_18_1","unstructured":"Pharmaceuticals and Medical Device Agency \u201cReview Reports \u201dhttps:\/\/www.pmda.go.jp\/review\u2010services\/drug\u2010reviews\/review\u2010information\/p\u2010drugs\/0020.html."},{"key":"e_1_2_9_19_1","unstructured":"Japan Pharmaceutical Manufactures Association \u201cClinical Data Package Summaries \u201dhttps:\/\/www.jpma.or.jp\/information\/evaluation\/results\/allotment\/shouninhinmoku.html."},{"key":"e_1_2_9_20_1","volume-title":"Partial Revision of \u2018Handling of Designation of Breakthrough Pharmaceuticals\u2019","author":"Ministry of Health, Labour and Welfare","year":"2023"},{"key":"e_1_2_9_21_1","volume-title":"Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting (PD\u20101\/PD\u2010L1)","author":"US Food and Drug Administration","year":"2021"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2104846"},{"key":"e_1_2_9_23_1","volume-title":"Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting (PI3K Inhibitor)","author":"US Food and Drug Administration","year":"2022"},{"key":"e_1_2_9_24_1","volume-title":"Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting (Melphalan Flufenamide)","author":"US Food and Drug Administration","year":"2022"},{"key":"e_1_2_9_25_1","volume-title":"Final Summary Minutes of the Oncologic Drugs Advisory Committee Meeting (Panobinostat)","author":"US Food and Drug Administration","year":"2014"},{"key":"e_1_2_9_26_1","volume-title":"Mandate, Objectives and Rules of Procedure for the Inter\u2010Committee Scientific Advisory Group (SAG) for Oncology","author":"European Medicines Agency","year":"2014"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu500"},{"key":"e_1_2_9_28_1","volume-title":"Amendment to \u2018Basic Principles on Global Clinical Trials (Reference Cases)\u2019","author":"Ministry of Health, Labour and Welfare","year":"2021"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0359"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2396"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2208954"},{"key":"e_1_2_9_32_1","volume-title":"Basic Principles on Japanese Clinical Trial Data for Drugs for Rare Diseases, etc., for Which Confirmatory Clinical Trials Have Been Conducted Only Overseas","author":"Ministry of Health, Labour and Welfare","year":"2024"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3540"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00371-5"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01018-w"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00592-2"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0805-y"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31957"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2081"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13879"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00357-1"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08685-w"},{"key":"e_1_2_9_43_1","unstructured":"US Food and Drug Administration \u201cExpanded Access \u201dhttps:\/\/www.fda.gov\/news\u2010events\/public\u2010health\u2010focus\/expanded\u2010access."},{"key":"e_1_2_9_44_1","volume-title":"Guideline on Compassionate Use of Medicinal Products, Pursuant to Article 83 of Regulation (EC) No 726\/2004","author":"European Medicines Agency","year":"2007"},{"key":"e_1_2_9_45_1","unstructured":"US Food and Drug Administration \u201cPhysician Request for a Single Patient IND for Compassionate or Emergency Use \u201dhttps:\/\/www.fda.gov\/about\u2010fda\/center\u2010drug\u2010evaluation\u2010and\u2010research\u2010cder\/physician\u2010request\u2010single\u2010patient\u2010ind\u2010compassionate\u2010or\u2010emergency\u2010use."},{"key":"e_1_2_9_46_1","unstructured":"European Medicines Agency \u201c2. Early Access 4. Named Patient Basis Access \u201dhttps:\/\/learning.eupati.eu\/mod\/book\/view.php?id=912&chapterid=891."},{"key":"e_1_2_9_47_1","volume-title":"Conduct of Clinical Trials Implemented on Humanitarian Grounds (Iyaku\u2010Yakushinhatsu 0913 No. 2; Issued September 13, 2024)","author":"Ministry of Health, Labour and Welfare","year":"2024"},{"key":"e_1_2_9_48_1","volume-title":"Notes on the Implementation of Patient\u2010Requested Medical Care and the Handling of Applications Under the Health Insurance Act and the Act on Assurance of Medical Care for Elderly People","author":"Ministry of Health, Labour and Welfare","year":"2025"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S468663"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2641"},{"key":"e_1_2_9_51_1","first-page":"s38","article-title":"Operational Status and Challenges of \u2018Expanded Access Trials\u2019 and \u2018Patient\u2010Requested Medical Care\u2019","volume":"23","author":"Fujiwara Y.","year":"2018","journal-title":"Japanese Journal of Pharmacoepidemiology\/Yakuzai ekigaku"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:53:01Z","timestamp":1782103981000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1111\/cts.70642"],"URL":"https:\/\/doi.org\/10.1111\/cts.70642","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70642"}}